Take­da scores a win for a rare type of lung can­cer, gear­ing up for a show­down with J&J

Four months af­ter J&J’s in­fused drug Ry­bre­vant scored the in­dus­try’s first win in a rare type of non-small cell lung can­cer (NSCLC), Take­da is fol­low­ing up with an oral op­tion for the small but des­per­ate pa­tient pop­u­la­tion.

The FDA grant­ed an ac­cel­er­at­ed ap­proval to Take­da’s oral TKI in­hibitor Exkiv­i­ty (mobo­cer­tinib) in metasta­t­ic NSCLC pa­tients with EGFR ex­on 20 gene mu­ta­tions who had pre­vi­ous­ly un­der­gone plat­inum-based chemother­a­py, the com­pa­ny an­nounced on Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.